PRMT5 determines the sensitivity to chemotherapeutics by governing stemness in breast cancer

No abstract is available for this paper.

• Publication year

  2018

• Venue

  Breast Cancer Research and Treatment

• Publication date

  2018-04-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1007/s10549-017-4597-6PMID 29185119
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Novel Copper Complexes That Inhibit the Proteasome and Trigger Apoptosis in Triple-Negative Breast Cancer Cells.

  2019cited by this paper
• Protein arginine methyltransferase 5 represses tumor suppressor miRNAs that down-regulate CYCLIN D1 and c-MYC expression in aggressive B-cell lymphoma

  2019cited by this paper
• Targeting PRMT5 Activity Inhibits the Malignancy of Hepatocellular Carcinoma by Promoting the Transcription of HNF4α

  2019cited by this paper
• A novel small-molecule antagonizes PRMT5-mediated KLF4 methylation for targeted therapy

  2019cited by this paper
• Overcoming Tamoxifen Resistance of Human Breast Cancer by Targeted Gene Silencing Using Multifunctional pRNA Nanoparticles.

  2017cited by this paper
• Elevated expression of protein arginine methyltransferase 5 predicts the poor prognosis of breast cancer

  2017cited by this paper
• miR-424(322)/503 is a breast cancer tumor suppressor whose loss promotes resistance to chemotherapy

  2017cited by this paper
• Heterogeneity of tumor cells in the bone microenvironment: Mechanisms and therapeutic targets for bone metastasis of prostate or breast cancer.

  2016cited by this paper
• The dual epigenetic role of PRMT5 in acute myeloid leukemia: gene activation and repression via histone arginine methylation

  2016cited by this paper
• Targeting methyltransferase PRMT5 eliminates leukemia stem cells in chronic myelogenous leukemia.

  2016cited by this paper
• MTAP deletion confers enhanced dependency on the PRMT5 arginine methyltransferase in cancer cells

  2016cited by this paper
• Disordered methionine metabolism in MTAP/CDKN2A-deleted cancers leads to dependence on PRMT5

  2016cited by this paper
• The PRMT5 arginine methyltransferase: many roles in development, cancer and beyond

  2015cited by this paper
• Interplay between arginine methylation and ubiquitylation regulates KLF4-mediated genome stability and carcinogenesis

  2015cited by this paper
• Genetic validation of the protein arginine methyltransferase PRMT5 as a candidate therapeutic target in glioblastoma.

  2014cited by this paper
• MicroRNA-30c inhibits human breast tumour chemotherapy resistance by regulating TWF1 and IL-11

  2013cited by this paper
• Overexpression of PRMT5 Promotes Tumor Cell Growth and Is Associated with Poor Disease Prognosis in Epithelial Ovarian Cancer

  2013cited by this paper
• Protein arginine methyltransferase 5 is essential for growth of lung cancer cells.

  2012cited by this paper
• Transcription Factor Positive Regulatory Domain 4 (PRDM4) Recruits Protein Arginine Methyltransferase 5 (PRMT5) to Mediate Histone Arginine Methylation and Control Neural Stem Cell Proliferation and Differentiation*

  2012cited by this paper
• Protein arginine methyltransferases and cancer

  2012cited by this paper
• The hallmarks of cancer

  2012cited by this paper
• Prmt5 is essential for early mouse development and acts in the cytoplasm to maintain ES cell pluripotency.

  2010cited by this paper
• EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer

  2010cited by this paper
• Survival of the fittest: cancer stem cells in therapeutic resistance and angiogenesis.

  2008cited by this paper
• Arginine methylation regulates the p53 response

  2008cited by this paper
• Chemotherapy resistance of glioblastoma stem cells

  2006cited by this paper
• Breast Cancer Molecular Subtypes Respond Differently to Preoperative Chemotherapy

  2005cited by this paper
• Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials.

  2005cited by this paper
• Migrating cancer stem cells — an integrated concept of malignant tumour progression

  2005cited by this paper
• Tumour stem cells and drug resistance

  2005cited by this paper
• Stem Cells,Cancer and Cancer Stem Cells

  2005cited by this paper
• Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer.

  2004cited by this paper
• Prognostic value of proliferation in invasive breast cancer: a review

  2004cited by this paper
• Negative regulation of transcription by the type II arginine methyltransferase PRMT5

  2002cited by this paper
• Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan.

  2001cited by this paper
• Stem cells, cancer, and cancer stem cells

  2001cited by this paper
• Paclitaxel versus doxorubicin as first-line single-agent chemotherapy for metastatic breast cancer: a European Organization for Research and Treatment of Cancer Randomized Study with cross-over.

  2000cited by this paper
• Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy.

  1999cited by this paper
• Different mechanisms of decreased drug accumulation in doxorubicin and mitoxantrone resistant variants of the MCF7 human breast cancer cell line.

  1991cited by this paper
• Pharmacological and biological evidence for differing mechanisms of doxorubicin resistance in two human tumor cell lines.

  1988cited by this paper

• PRMT5 upregulates KCNMB4 expression via histone methylation to promote paclitaxel resistance in advanced nasopharyngeal carcinoma

  2026cites this paper
• Targeting PRMT5 in Adult T-Cell Leukemia/Lymphoma: Opportunities and Challenges

  2026cites this paper
• Targeting PRMT5 in cancer: Mechanistic insights and clinical progress.

  2025cites this paper
• Arginine methylation in cancer: mechanisms and therapeutic implications

  2025cites this paper
• Therapeutic targeting of protein arginine methyltransferases reduces breast cancer progression by disrupting angiogenic pathways

  2025cites this paper
• Epigenetic mechanisms in non-small cell lung cancer therapy and chemoresistance.

  2025cites this paper
• Epigenetic regulation of cancer stemness

  2025cites this paper
• Nanoparticle albumin-bound paclitaxel (nab-Paclitaxel): Bridging pharmacology and translational medicine in breast cancer.

  2025cites this paper
• Protein arginine methyltransferase 5 confers the resistance of triple-negative breast cancer to nanoparticle albumin-bound paclitaxel by enhancing autophagy through the dimethylation of ULK1.

  2024cites this paper
• Therapeutic targeting potential of the protein lysine and arginine methyltransferases to reverse cancer chemoresistance

  2024cites this paper
• Role of PRMT1 and PRMT5 in Breast Cancer

  2024cites this paper
• Research progress on PRMTs involved in epigenetic modification and tumour signalling pathway regulation (Review)

  2023cites this paper
• PRMT5 as a Potential Therapeutic Target in MYC-Amplified Medulloblastoma

  2023cites this paper
• Effects of RNA methylation on Tumor angiogenesis and cancer progression

  2023cites this paper
• Promising role of protein arginine methyltransferases in overcoming anti-cancer drug resistance.

  2023cites this paper
• Autophagy dictates sensitivity to PRMT5 inhibitor in breast cancer

  2023cites this paper
• PRMT5 reduces immunotherapy efficacy in triple-negative breast cancer by methylating KEAP1 and inhibiting ferroptosis

  2023cites this paper
• TRAF6 Promotes PRMT5 Activity in a Ubiquitination-Dependent Manner

  2023cites this paper
• Mep50 is essential for embryonic development in medaka fish.

  2023cites this paper
• The nociceptin receptor promotes autophagy through NF-kB signaling and is transcriptionally regulated by E2F1 in HCC

  2022cites this paper
• PRMT5 regulates RNA m6A demethylation for doxorubicin sensitivity in breast cancer.

  2022cites this paper
• Novel Chemicals Derived from Tadalafil Exhibit PRMT5 Inhibition and Promising Activities against Breast Cancer

  2022cites this paper
• Protein Arginine Methyltransferase 5 (PRMT5) Inhibitors in Oncology Clinical Trials: A review

  2022cites this paper
• Protein arginine methyltransferases 5 (PRMT5) affect multiple stages of autophagy and modulate autophagy-related genes in controlling breast cancer tumorigenesis.

  2022cites this paper
• Essential Roles of PRMT5-MEP50 Complex Formation and Cancer Therapy

  2021cites this paper
• Essential Roles of PRMT5-MEP50 Complex Formation and Cancer Therapy

  2021cites this paper
• Cancer synthetic vulnerabilities to protein arginine methyltransferase inhibitors.

  2021cites this paper
• Protein Arginine Methyltransferase 5 Promotes Esophageal Squamous Cell Carcinoma Proliferation and Metastasis via LKB1/AMPK/mTOR Signaling Pathway

  2021cites this paper
• Protein arginine methyltransferases: promising targets for cancer therapy

  2021cites this paper
• Protein arginine methylation: from enigmatic functions to therapeutic targeting

  2021cites this paper
• PRMT5-mediated arginine methylation activates AKT kinase to govern tumorigenesis

  2021cites this paper
• Systemic therapies for salivary gland adenoid cystic carcinoma.

  2021cites this paper
• Comparative proteomic analysis of protein methylation provides insight into the resistance of hepatocellular carcinoma to 5-fluorouracil.

  2020cites this paper
• The potential mechanisms of piRNA to induce hepatocellular carcinoma in human.

  2020cites this paper
• EPZ015666, a selective protein arginine methyltransferase 5 (PRMT5) inhibitor with an antitumour effect in retinoblastoma.

  2020cites this paper
• Histone methyltransferase and drug resistance in cancers

  2020cites this paper
• Methylation of the central transcriptional regulator KLF4 by PRMT5 is required for DNA end resection and recombination.

  2020cites this paper
• PRMT5-dependent transcriptional repression of c-Myc target genes promotes gastric cancer progression

  2020cites this paper
• Protein arginine methyltransferase 5: A novel therapeutic target for triple‐negative breast cancers

  2019cites this paper
• Role of protein arginine methyltransferase 5 in human cancers.

  2019cites this paper
• NF-κB/mTOR/MYC Axis Drives PRMT5 Protein Induction After T Cell Activation via Transcriptional and Non-transcriptional Mechanisms

  2019cites this paper
• Epigenetic arginine methylation in breast cancer: emerging therapeutic strategies.

  2019cites this paper
• Protein arginine methyltransferase 5 represses tumor suppressor miRNAs that down-regulate CYCLIN D1 and c-MYC expression in aggressive B-cell lymphoma

  2019cites this paper
• Novel Copper Complexes That Inhibit the Proteasome and Trigger Apoptosis in Triple-Negative Breast Cancer Cells.

  2019cites this paper
• Microenvironmental Regulation of Long Noncoding RNA LINC01133 Promotes Cancer Stem Cell‐Like Phenotypic Traits in Triple‐Negative Breast Cancers

  2019cites this paper
• A novel small-molecule antagonizes PRMT5-mediated KLF4 methylation for targeted therapy

  2019cites this paper
• Targeting PRMT5 Activity Inhibits the Malignancy of Hepatocellular Carcinoma by Promoting the Transcription of HNF4α

  2019cites this paper
• GGNBP2 suppresses triple-negative breast cancer aggressiveness through inhibition of IL-6/STAT3 signaling activation

  2018cites this paper